GetChain News
中简 中繁 EN
GetChain News
Toggle sidebar

Financing/Fundraising

News linked to both this project and an event.

Swiss Crypto Valley’s blockchain funding grew by 37% in 2025, with TON Network transactions dominating

According to Cointelegraph, Switzerland’s Crypto Valley raised a total of $728 million in blockchain funding in 2025—a 37% year-on-year increase—and accounted for 47% of Europe’s blockchain venture capital. The largest single contribution came from TON Network’s $400 million funding round; Sygnum Bank raised $58 million; the M0 stablecoin platform raised $40 million; Impossible Cloud Network and CratD2C raised $34 million and $30 million, respectively. The report states that global blockchain funding totaled $15.5 billion, up 30% year-on-year, but deal volume declined by 32%, reflecting a trend toward concentration of capital in a smaller number of large-scale projects. The number of active blockchain companies in Crypto Valley rose to 1,766, while the number of unicorns fell from 17 to 10, primarily due to market conditions.

AlphaTON Capital Plans to Raise $43 Million to Expand AI Computing Infrastructure

According to The Block, AlphaTON Capital has announced plans to raise $43 million through a strategic partnership with Vertical Data Inc. to expand its AI compute infrastructure; the transaction is expected to close in Q2 2026. AlphaTON CEO Brittany Kaiser stated that the funding will be used to deploy additional NVIDIA B300 GPUs, with the core objective of advancing the convergence of AI, digital assets, and confidential computing—and scaling up the platform’s overall compute capacity. On the business front, AlphaTON not only holds a substantial amount of TON tokens as corporate treasury assets but also actively participates in building infrastructure for the Telegram and TON ecosystems, with key investment focus areas including Cocoon, Telegram’s decentralized AI platform. Background-wise, AlphaTON was formed through the restructuring and transformation of former biotech public company Portage Biotech Inc., which had previously focused on cancer therapy research; the company completed the spin-off of its cancer therapy subsidiary in February this year.